ABBV-453 + daratumumab + dexamethasone

ABBV-453 + daratumumab + dexamethasone is a three-drug investigational combination therapy evaluated in patients with relapsed/refractory multiple myeloma. ABBV-453 is an investigational, orally bioavailable small molecule, thought to act as an allosteric BCL-2 inhibitor, targeting plasma cells with t(11;14) translocation or high BCL-2 expression. Daratumumab is a monoclonal antibody that targets CD38 on the surface of myeloma cells, leading to cell death via mechanisms such as antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Dexamethasone is a synthetic glucocorticoid used as an immunosuppressant and antineoplastic agent. The combination is under study in Phase 1/2 trials for patients with relapsed or refractory multiple myeloma, aiming to improve outcomes over standard treatments[2][3][5][6][7].

Other names

daratumumabdexamethasone